Unexplained Recurrent Pregnancy Loss and Emerging Endometrial Biology: A Clinically Oriented Narrative Review.

Authors

Daichi Inoue

Published in

Cureus. Volume 18. Issue 8. Pages e114105. Epub Aug 07, 2026.

Abstract

A substantial proportion of couples who experience recurrent pregnancy loss (RPL) complete a full guideline-based evaluation without an identifiable cause and are given a diagnosis of unexplained RPL. This category should be interpreted as the current limitation of clinically validated biological explanation rather than as the absence of underlying pathology, and it is within this diagnostic gap that interest in emerging endometrial biology has grown. Recent advances in endometrial biology have generated substantial interest in three closely related investigational domains: the endometrial microbiome, chronic endometritis (CE), and the endometrial immune milieu. Each domain has independently been associated with reproductive failure in observational research, and growing evidence suggests potential biological interactions among them. However, significant methodological heterogeneity, absence of standardized diagnostic criteria, and insufficient prospective validation currently preclude routine clinical implementation. This narrative review synthesizes current evidence in each of these domains and weighs their relevance to how unexplained RPL is managed. The review concludes that abnormalities involving endometrial microbial composition, chronic endometrial inflammation, and local immune dysregulation represent biologically plausible contributors to unexplained pregnancy loss in selected women, but that the principal barriers to clinical adoption are reproducibility, methodological standardization, and demonstrated clinical utility rather than biological plausibility alone. Major professional guidelines currently advise against routine use of these tests outside a research context. Emerging endometrial biology should therefore be interpreted as a framework for ongoing scientific inquiry, not as a basis for expanded clinical testing. Incorporation into routine practice will require standardized methodology, independent multicenter validation, and prospective demonstration that diagnosis and treatment improve clinically meaningful reproductive outcomes.

PMID:
42703380
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.